Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001

Archives of Pediatrics and Adolescent Medicine

Volumn 159, Issue 12, 2005, Pages 1136-1144

  Zhou, Fangjun ^a   Santoli, Jeanne ^a   Messonnier, Mark L ^a   Yusuf, Hussain R ^a,b   Shefer, Abigail ^a   Chu, Susan Y ^a   Rodewald, Lance ^a   Harpaz, Rafael ^a  

^a CENTERS FOR DIS CONTR AND PREV   (United States)

^b UNICEF   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS TOXOID; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; INACTIVATED VACCINE; MEASLES MUMPS RUBELLA VACCINE; POLIOMYELITIS VACCINE;

ABSENTEEISM; ANAPHYLAXIS; ARTHRALGIA; ARTHRITIS; ARTICLE; ASEPTIC MENINGITIS; CHILD HEALTH CARE; COST BENEFIT ANALYSIS; COST CONTROL; CRYING; DRUG ERUPTION; DRUG FEVER; ECONOMIC EVALUATION; ENCEPHALITIS; FEBRILE CONVULSION; FOLLOW UP; HEALTH PROGRAM; HERPES ZOSTER; HUMAN; IMMUNIZATION; INFANT; MUSCLE HYPOTONIA; PARENT; PAROTITIS; PNEUMONIA; POPULATION RESEARCH; PRIORITY JOURNAL; PUBLICATION; SEIZURE; THROMBOCYTOPENIC PURPURA; TRAVEL; UNITED STATES; VACCINATION REACTION;

CHICKENPOX; CHILD; CHILD, PRESCHOOL; COSTS AND COST ANALYSIS; DIPHTHERIA; DIRECT SERVICE COSTS; FOLLOW-UP STUDIES; HAEMOPHILUS INFECTIONS; HUMANS; IMMUNIZATION; IMMUNIZATION PROGRAMS; IMMUNIZATION SCHEDULE; INCIDENCE; INFANT; MEASLES; MODELS, ECONOMIC; MUMPS; POLIOMYELITIS; RETROSPECTIVE STUDIES; RUBELLA; TETANUS; UNITED STATES; VACCINES; WHOOPING COUGH;

EID: 28744443427     PISSN: 10724710     EISSN: 10724710     Source Type: Journal    
DOI: 10.1001/archpedi.159.12.1136     Document Type: Article

References (100)

1. Koplan JP, Schoenbaum SC, Smith DG, Weinstein MC, Fraser DW. Pertussis vaccine: an analysis of benefits, risks and costs. N Engl J Med. 1979;301:906-911.
2. Hinman AR, Koplan JP. Pertussis and pertussis vaccine: reanalysis of benefits, risks, and costs. JAMA. 1984;251:3109-3113.
3. Hinman AR, Koplan JP. Pertussis and pertussis vaccine: further analysis of benefits, risks and costs. Dev Biol Stand. 1985;61:429-437.
4. Hatziandreu EJ, Palmer CS, Brown RE, Halpern MT. A Cost Benefit Analysis for the Diphtheria Tetanus-Pertussis (DTP) Vaccine: Report Prepared for the Centers for Disease Control and Prevention. Arlington, Va: Battelle Inc; 1994.
5. Ekwueme DU, Strebel PM, Hadler SC, Meltzer MI, Allen JW, Livengood JR. Economic evaluation of use of diphtheria, tetanus, and acellular pertussis vaccine or diphtheria, tetanus, and whole-cell pertussis vaccine in the United States, 1997. Arch Pediatr Adolesc Med. 2000;154:797-803.
6. Cochi SL, Broome CV, Hightower AW. Immunization of US children with Haemophilus influenzae type b polysaccharide vaccine: a cost-effectiveness model of strategy assessment. JAMA. 1985;253:521-529.
7. Hay JW, Daum RS. Cost-benefit analysis of two strategies for prevention of Haemophilus influenzae type b infection. Pediatrics. 1987;80:319-329.
8. Hay JW, Daum RS. Cost-benefit analysis of Haemophilus influenzae type b prevention: conjugate vaccination at eighteen months of age. Pediatr Infect Dis J. 1990;9:246-252.
9. Hatziandreu EJ, Brown RE. A Cost Benefit Analysis of the Haemophilus influenzae Type B (Hib) Vaccine: Report Prepared for the Centers for Disease Control and Prevention. Arlington, Va: Battelle Inc; 1995.
10. Zhou F, Bisgard KM, Yusuf HR, Deuson RR, Bath SK, Murphy TV. Impact of universal Haemophilus influenzae type b vaccination starting at 2 months of age in the United States: an economic analysis. Pediatrics. 2002;110:653-661.
11. Weisbrod B. Costs and benefits of medical research: a case study of poliomyelitis. J Polit Econ. 1971;79:527-544.
12. Fudenberg HH. Fiscal returns of biomedical research. J Invest Dermatol. 1973;61:321-329.
13. Hatziandreu EJ, Palmer CS, Halpern MT, Brown RE. A Cost Benefit Analysis of the OPV Vaccine: Report Prepared for the Centers for Disease Control and Prevention. Arlington, Va: Battelle Inc; 1994.
14. Miller MA, Sutter RW, Strebel PM, Hadler SC. Cost-effectiveness of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule. JAMA. 1996;276:967-971.
15. Axnick NW, Shavell SM, Witte JJ. Benefits due to immunization against measles. Public Health Rep. 1969;84:673-680.
16. Witte JJ, Axnick NW. The benefits from 10 years of measles immunization in the United States. Public Health Rep. 1975;90:205-207.
17. Albritton RB. Cost-benefits of measles eradication: effects of a federal intervention. Policy Anal. 1978;4:1-21.
18. Koplan JP, Preblud SR. A benefit-cost analysis of mumps vaccine. AJDC. 1982;136:362-364.
19. Schoenbaum SC, Hyde JN Jr, Barthoshesky L, Crampton K. Benefit-cost analysis of rubella vaccination policy. N Engl J Med. 1976;294:306-310.
20. White CC, Koplan JP, Orenstein WA. Benefits, risks and costs of immunization for measles, mumps and rubella. Am J Public Health. 1985;75:739-744.
21. Hatziandreu EJ, Brown RE, Halpern MT. A Cost Benefit Analysis of the Measles-Mumps-Rubella (MMR) Vaccine: Report Prepared for the Centers for Disease Control and Prevention. Arlington, Va: Battelle Inc; 1994.
22. Zhou F, Reef S, Massoudi M, et al. An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States. J Infect Dis. 2004;189:S131-S145.
23. Mulley AG, Silverstein MD, Dienstag JL. Indications for use of hepatitis B vaccine, based on cost-effectiveness analysis. N Engl J Med. 1982;307:644-652.
24. Bloom BS, Hillman AL, Fendrick AM, Schwartz JS. A reappraisal of hepatitis B virus vaccination strategies using cost-effectiveness analysis. Ann Intern Med. 1993;118:298-306.
25. Bergus G, Meis S. Hepatitis B vaccination: a cost analysis. Iowa Med. 1995;85:209-211.
26. Margolis HS, Coleman PJ, Brown RE, Mast EE, Sheingold SH, Arevalo JA. Prevention of hepatitis B virus transmission by immunization: an economic analysis of current recommendations. JAMA. 1995;274:1201-1208.
27. Hadler SC. Cost benefit of combining antigens. Biologicals. 1994;22:415-418.
28. Fendrick AM, Lee JH, LaBarge C, Glick HA. Clinical and economic impact of a combination Haemophilus influenzae and hepatitis B vaccine: estimating cost-effectiveness using decision analysis. Arch Pediatr Adolesc Med. 1999;153:126-136.
29. Preblud SR, Orenstein WA, Koplan JP, Bart KJ, Hinman AR. A benefit-cost analysis of a childhood varicella vaccination programme. Postgrad Med J. 1985;61(suppl 4):17-22.
30. Lieu TA, Cochi SL, Black SB, et al. Cost-effectiveness of a routine varicella vaccination program for US children. JAMA. 1994;271:375-381.
31. Huse DM, Meissner HC, Lacey MJ, Oster G. Childhood vaccination against chickenpox: an analysis of benefits and costs. J Pediatr. 1994;124:869-874.
32. Lieu TA, Ray GT, Black SB, et al. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA. 2000;283:1460-1468.
33. Miller MA, Hinman AR. Cost-benefit and cost-effectiveness analysis of vaccine policy. In: Plotkin SA, Orenstein WA, eds. Vaccines. Philadelphia, Pa:WB Saunders Co; 1999:1075-1088.
34. Centers for Disease Control and Prevention. Ten great public health achievements - United States, 1900-1999. MMWR Morb Mortal Wkly Rep. 1999;48:241-243.
35. Centers for Disease Control and Prevention. Impact of vaccines universally recommended for children - United States, 1990-1998. MMWR Morb Mortal Wkly Rep. 1999;48:243-248.
36. Seward JF, Watson BM, Peterson CL, et al. Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA. 2002;287:606-611.
37. Nguyen HQ, Jumaan AO, Seward JF. Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N Engl J Med. 2005;352:450-458.
38. Use of diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine as a five-dose series: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2000;49(RR-13):1-8.
39. Atkinson W, Wolfe S, eds. Epidemiology and Prevention for Vaccine-Preventable Disease. 7th ed. Washington, DC: Public Health Foundation; 2003.
40. Poliomyelitis prevention in the United States: updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2000;49(RR-5):1-22.
41. Redd S, Markowitz LE, Katz SL. Measles vaccine. In: Plotkin S, Orenstein WA, eds. Vaccines. Philadelphia, Pa: WB Saunders Co; 1999:409-439.
42. Plotkin S, Wharton M. Mumps vaccine. In: Plotkin S, Orenstein WA, eds. Vaccines. Philadelphia, Pa: WB Saunders Co; 1999:267-292.
43. Plotkin S. Rubella vaccine. In: Plotkin S, Orenstein WA, eds. Vaccines. Philadelphia, Pa: WB Saunders Co; 1999:409-439.
44. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1996;45(RR-11):1-36.
45. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2000;45(RR-9):1-22.
46. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997;46(RR-7):1-25.
47. Haemophilus B conjugate vaccines for prevention of Haemophilus influenzae type B disease among infants and children two months of age and older: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep. 1991;40(RR-1):1-7.
48. Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep. 1998;47(RR-8):1-57.
49. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep. 1991;40(RR-13):1-25.
50. Murata R. Immunization against diphtheria in Japan. Jpn J Med Sci Biol. 1981;34:329-354.
51. Romanus V, Jonsell R, Bergquist SO. Pertussis in Sweden after the cessation of general immunization in 1979. Pediatr Infect Dis J. 1987;6:364-371.
52. Collins SA. Age incidence of the common communicable diseases in children. Public Health Rep. 1929;44:763-826.
53. Granoff DM, Basden M. Haemophilus influenzae infections in Fresno County, California: a prospective study of the effects of age, race, and contact with a case on incidence of disease. J Infect Dis. 1980;141:40-46.
54. Ward JI, Zangwill KM. Haemophilus influenzae vaccines. In: Plotkin S, Orenstein WA, eds. Vaccines. Philadelphia, Pa: WB Saunders Co; 1999:183-211.
55. Langmuir AD. Medical importance of measles. AJDC. 1962;103:224-226.
56. Wassilak SG, Orenstein WA, Sutter RW. Tetanus toxoid. In: Plotkin S, Orenstein WA, eds. Vaccines. Philadelphia, Pa: WB Saunders Co; 1999:441-474.
57. Mortimer EA Jr, Wharton M. Diphtheria toxoid. In: Plotkin S, Orenstein WA, eds. Vaccines. Philadelphia, Pa: WB Saunders Co; 1999:140-157.
58. Edwards KM, Decker MD, Mortimer EA Jr. Pertussis vaccine. In: Plotkin S, Orenstein WA, eds. Vaccines. Philadelphia, Pa: WB Saunders Co; 1999:293-344.
59. Centers for Disease Control and Prevention. Summary of notifiable disease, United States, 1990. MMWR Morb Mortal Wkly Rep. 1991;39:53-61.
60. Tanaka M, Vitek CR, Pascual FB, Bisgard KM, Tate JE, Murphy TV. Trends in pertussis among infants in the United States, 1980-1999. JAMA. 2003;290:2968-2975.
61. Lee GM, Lett S, Schauer S, et al. Societal costs and morbidity of pertussis in adolescents and adults. Clin Infect Dis. 2004;39:1572-1580.
62. Horstmann DM. Poliomyelitis: severity and type of disease in different age groups. Ann N Y Acad Sci. 1955;61:956-967.
63. Codd MB, Mulder DW, Kurland LT, Beard CM, O'Fallon WM. Poliomyelitis in Rochester, Minnesota, 1935-1955: epidemiology and long-term sequelae: a preliminary report. In: Halstead LS, Wiechers DO, eds. Late Effects of Poliomyelitis. Miami, Fla: Symposia Foundation; 1985:121-134.
64. Alcock AJ, Hildes JA, Kaufert PA, Kaufert JM, Bickford J. Respiratory poliomyelitis: a follow-up study. CMAJ. 1984;130:1305-1310.
65. Ramlow J, Alexander M, LaPorte R, Kaufmann C, Kuller L. Epidemiology of the post-polio syndrome. Am J Epidemiol. 1992;136:769-786.
66. Halstead LS, Wiechers DO, Rossi CD. Results of a survey of 201 polio survivors. South Med J. 1985;78:1281-1287.
67. Halstead LS, Silver JK. Nonparalytic polio and postpolio syndrome. Am J Phys Med Rehabil. 2000;79:13-18.
68. Plotkin S, Murdin AD, Vidor E. Inactivated polio vaccine. In: Plotkin S, Orenstein WA, eds. Vaccines. Philadelphia, Pa: WB Saunders Co; 1999:345-363.
69. Pelletier L, Chung P, Duclos P, Manga P, Scott J. A benefit-cost analysis of twodose measles immunization in Canada. Vaccine. 1998;16:989-996.
70. Chu YW, Korb J, Sakamoto KM. Idiopathic thrombocytopenic purpura. Pediatr Rev. 2000;21:95-104.
71. Modlin JF, Halsey NA, Eddins DL, et al. Epidemiology of subacute sclerosing panencephalitis. J Pediatr. 1979;94:231-236.
72. Centers for Disease Control. Subacute sclerosing panencephalitis surveillance - United States. MMWR Morb Mortal Wkly Rep. 1982;31:585-588.
73. Miller E, Cradock-Watson JE, Pollock TM. Consequences of confirmed maternal rubella at successive stages of pregnancy. Lancet. 1982;2:781-784.
74. South MA, Sever JL. Teratogen update: the congenital rubella syndrome. Teratology. 1985;31:297-307.
75. Galil K, Brown C, Lin F, Seward J. Hospitalizations for varicella in the United States, 1988 to 1999. Pediatr Infect Dis J. 2002;21:931-935.
76. Meyer PA, Seward JF, Jumaan AO, Wharton M. Varicella mortality: trends before vaccine licensure in the United States, 1970-1994. J Infect Dis. 2000;182:383-390.
77. Margolis HS, Alter MJ, Hadler SC. Hepatitis B: evolving epidemiology and implications for control. Semin Liver Dis. 1991;11:84-92.
78. McQuillan GM, Coleman PJ, Kruszon-Moran D, Moyer LA, Lambert SB, Margolis HS. Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health. 1999;89:14-18.
79. Arevalo JA, Washington AE. Cost-effectiveness of prenatal screening and immunization for hepatitis B virus. JAMA. 1988;259:365-369.
80. Krahn M, Detsky AS. Should Canada and the United States universally vaccinate infants against hepatitis B? a cost-effectiveness analysis. Med Decis Making. 1993;13:4-20.
81. Beasley RP. Hepatitis B virus: the major etiology of hepatocellular carcinoma. Cancer. 1988;61:1942-1956.
82. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22,707 men in Taiwan. Lancet. 1981;2:1129-1133.
83. McMahon BJ, Alberts SR, Wainwright RB, Bulkow L, Lanier AP. Hepatitis B-related sequelae: prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. Arch Intern Med. 1990;150:1051-1054.
84. Andre FE, Zuckerman AJ. Review: protective efficacy of hepatitis B vaccines in neonates. J Med Virol. 1994;44:144-151.
85. HCUPnet Web site. Available at: http://www.ahrq.gov/data/hcup/hcupnet. htm. Accessed December 27, 2001.
86. Marketscan Database [computer program]. Ann Arbor, Mich: Medstat Group Inc; 2000.
87. Boyle CA, Decoufle P, Yeargin-Allsopp M. Prevalence and health impact of developmental disabilities in US children. Pediatrics. 1994;93:399-403.
88. Halpern M, Rentz A, Murray M. Cost of illness of epilepsy in the US: comparison of patient-based and population-based estimates. Neuroepidemiology. 2000;19:87-99.
89. Chambers JG, Wolman JM. What Can We Learn From State Data Systems About the Cost of Special Education: A Case Study of Ohio. Palo Alto, Calif: Center for Special Education Finance, American Institutes for Research; 1998.
90. Iregui M, Malen J, Tuteur P, Lynch J, Holtzman MJ, Kollef MH. Determinants of outcome for patients admitted to a long-term ventilator unit. South Med J. 2002;95:310-317.
91. Davis H, Lefrak SS, Miller D, Malt S. Prolonged mechanically assisted ventilation: an analysis of outcome and charges. JAMA. 1980;243:43-45.
92. Rotary Club of Santa Monica. Payment options for senior housing and residential care. Available at: http://www.helpguide.org/elder/ paying_for_senior_housing_residential_care.htm. Accessed August 10, 2004.
93. Rosen RL, Bone RC. Economics of mechanical ventilation. Clin Chest Med. 1988;9:163-169.
94. Mohr PE, Feldman JJ, Dunbar JL, et al. The societal costs of severe to profound hearing loss in the United States. Int J Technol Assess Health Care. 2000;16:1120-1135.
95. Haddix AE, Teutch SM, Corso PS. Prevention Effectiveness: A Guide to Decision Analysis and Economic Evaluation. New York, NY: Oxford University Press; 2003.
96. Centers for Disease Control and Prevention. National, state, and urban area vaccination coverage levels among children aged 19-35 months - United States, 2000. MMWR Morb Mortal Wkly Rep. 2001;50:637-641.
97. Santoli JM, Rodewald LE, Maes EF, Battaglia MP, Coronado VG. Vaccines for Children program, United States, 1997. Pediatrics. 1999;104:e15.
98. Rodewald LE, Szilagyi PG, Holl J, Shone LR, Zwanziger J, Raubertas RF. Health insurance for low-income working families: effect on the provision of immunizations to preschool-age children. Arch Pediatr Adolesc Med. 1997;151:798-803.
99. National Vaccine Advisory Committee. Strategies to sustain success in childhood immunizations. JAMA. 1999;282:363-370.
100. Marshall GS, Gellin BG. Challenges to vaccine safety. Prim Care. 2001;28:853-868.